The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast : A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization studyDOWNS-KELLY, Erinn; YODER, Brian J; STOLER, Mark et al.The American journal of surgical pathology. 2005, Vol 29, Num 9, pp 1221-1227, issn 0147-5185, 7 p.Article

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology group (SWOG 9349)BLAYNEY, Douglas W; LEBLANC, Michael L; GROGAN, Thomas et al.Journal of clinical oncology. 2003, Vol 21, Num 13, pp 2466-2473, issn 0732-183X, 8 p.Article

Alteration of SMRT tumor suppressor function in transformed non-hodgkin lymphomasSONG, Lynda; ZLOBIN, Andrei; GALIEGUE-ZOUITINA, Sylvie et al.Cancer research (Baltimore). 2005, Vol 65, Num 11, pp 4554-4561, issn 0008-5472, 8 p.Article

Analytical validation and interobserver reproducibility of EnzMet GenePro : A second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breastDOWNS-KELLY, Erinn; PETTAY, James; HAINFELD, James et al.The American journal of surgical pathology. 2005, Vol 29, Num 11, pp 1505-1511, issn 0147-5185, 7 p.Article

Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphomaGASCOYNE, R. D.Hematology/oncology clinics of North America. 1997, Vol 11, Num 5, issn 0889-8588, v,847-862 [17 p.]Article

Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphomaDALTON, W. S.Hematology/oncology clinics of North America. 1997, Vol 11, Num 5, issn 0889-8588, viii,975-986 [13 p.]Article

Targeted therapy for lymphoma with peptidesLAM, K. S; ZHAO, Z.-G.Hematology/oncology clinics of North America. 1997, Vol 11, Num 5, issn 0889-8588, viii,1007-1019 [14 p.]Article

Long-term follow-up of platinum-based lymphoma salvage regimens : The M.D. Anderson cancer center experienceRODRIGUEZ-MONGE, E. J; CABANILLAS, F.Hematology/oncology clinics of North America. 1997, Vol 11, Num 5, issn 0889-8588, vii,937-947 [12 p.]Article

Treatment considerations in the elderly patient with lymphomaCONNORS, J. M; O'REILLY, S. E.Hematology/oncology clinics of North America. 1997, Vol 11, Num 5, issn 0889-8588, vii,949-961 [14 p.]Article

Tumor origin and CD20 expression in posttbansplant lymphoproliferative disorder occurring in solid organ transplant recipients: Implications for immune-based therapyGULLEY, Margaret L; SWINNEN, Lode J; PLAISANCE, Kerry T et al.Transplantation. 2003, Vol 76, Num 6, pp 959-964, issn 0041-1337, 6 p.Article

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromesBELLAMY, William T; RICHTER, Lynne; SIRJANI, Davuud et al.Blood. 2001, Vol 97, Num 5, pp 1427-1434, issn 0006-4971Article

Follicular lymphomas : Do histologic subtypes predict outcome?MILLER, T. P; LEBLANC, M; GROGAN, T. M et al.Hematology/oncology clinics of North America. 1997, Vol 11, Num 5, issn 0889-8588, vi,893-900 [9 p.]Article

BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemiaAKARCA, Ayse U; SHENDE, Vishvesh H; RAMSAY, Alan D et al.British journal of haematology. 2013, Vol 162, Num 6, pp 848-851, issn 0007-1048, 4 p.Article

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosisTOME, Margaret E; JOHNSON, David B. F; RIMSZA, Lisa M et al.Blood. 2005, Vol 106, Num 10, pp 3594-3601, issn 0006-4971, 8 p.Article

Gene expression profile of serial samples of transformed B-cell lymphomasDE VOS, Sven; HOFMANN, Wolf-Karsten; GROGAN, Thomas M et al.Laboratory investigation. 2003, Vol 83, Num 2, pp 271-285, issn 0023-6837, 15 p.Article

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma : A Southwest Oncology Group StudyGAYNOR, Ellen R; UNGER, Joseph M; MILLER, Thomas P et al.Journal of clinical oncology. 2001, Vol 19, Num 3, pp 750-755, issn 0732-183XArticle

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's diseasePRESS, Oliver W; LEBLANC, Michael; LICHTER, Allen S et al.Journal of clinical oncology. 2001, Vol 19, Num 22, pp 4238-4244, issn 0732-183XArticle

Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphomaSTOPECK, Alison T; GESSNER, Andrea; MILLER, Thomas P et al.Clinical cancer research. 2000, Vol 6, Num 10, pp 3904-3909, issn 1078-0432Article

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative DisorderSWINNEN, Lode J; LEBLANC, Michael; GROGAN, Thomas M et al.Transplantation. 2008, Vol 86, Num 2, pp 215-222, issn 0041-1337, 8 p.Article

Metallographic in situ hybridization : In situ techniquesPOWELL, Richard D; PETTAY, James D; POWELL, William C et al.Human pathology. 2007, Vol 38, Num 8, pp 1145-1159, issn 0046-8177, 15 p.Article

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patientsBERENSON, James R; CROWLEY, John J; GROGAN, Thomas M et al.Blood. 2002, Vol 99, Num 9, pp 3163-3168, issn 0006-4971Article

The Burkitt-like lymphomas : a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical featuresBRAZIEL, Rita M; ARBER, Daniel A; FISHER, Richard I et al.Blood. 2001, Vol 97, Num 12, pp 3713-3720, issn 0006-4971Article

Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphomaWILKINSON, Sarah T; VANPATTEN, Kristie A; FERNANDEZ, Diane R et al.Blood. 2012, Vol 119, Num 6, pp 1459-1467, issn 0006-4971, 9 p.Article

Phase II study of paclitaxel and Valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyFRACASSO, Paula M; BRADY, Mark F; MOORE, David H et al.Journal of clinical oncology. 2001, Vol 19, Num 12, pp 2975-2982, issn 0732-183XArticle

Page / 2